{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:33:01Z","timestamp":1790548381180,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10852-1","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:04:12Z","timestamp":1753419852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evidence based molecular pathways, available drug targets, pre- clinical animal models and future disease modifying treatments of huntington\u2019s disease"],"prefix":"10.1007","volume":"52","author":[{"given":"Falguni","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Dobhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daksh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachchida Nand","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmendra Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"1","key":"10852_CR1","first-page":"1","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP et al (2015) Huntington disease. Nat Reviews Disease Primers 1(1):1\u201321","journal-title":"Nat Reviews Disease Primers"},{"issue":"10","key":"10852_CR2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ et al (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Reviews Neurol 16(10):529\u2013546","journal-title":"Nat Reviews Neurol"},{"key":"10852_CR3","doi-asserted-by":"crossref","unstructured":"Hickey P, Stacy M (2015) Taxonomy and Clinical Features of Movement Disorders. Movement Disorders,: pp. 3\u201322","DOI":"10.1016\/B978-0-12-405195-9.00001-9"},{"issue":"3","key":"10852_CR4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JHD-210523","volume":"11","author":"CL Chase","year":"2022","unstructured":"Chase CL et al (2022) Searching for answers: Information-Seeking by young people At-Risk for huntington\u2019s disease. J Huntington\u2019s Disease 11(3):337\u2013346","journal-title":"J Huntington\u2019s Disease"},{"issue":"6","key":"10852_CR5","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/cells9061514","volume":"9","author":"AS Taran","year":"2020","unstructured":"Taran AS et al (2020) Huntington\u2019s Disease\u2014An outlook on the interplay of the HTT protein, microtubules and actin cytoskeletal components. Cells 9(6):1514","journal-title":"Cells"},{"key":"10852_CR6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijbiomac.2021.03.113","volume":"181","author":"C Wells","year":"2021","unstructured":"Wells C et al (2021) The role of amyloid oligomers in neurodegenerative pathologies. Int J Biol Macromol 181:582\u2013604","journal-title":"Int J Biol Macromol"},{"key":"10852_CR7","first-page":"100687","volume-title":"Putative role of immune reactions in the mechanism of tardive dyskinesia","author":"AJ Loonen","year":"2023","unstructured":"Loonen AJ (2023) Putative role of immune reactions in the mechanism of tardive dyskinesia. Brain, Behavior, & Immunity-Health, p 100687"},{"issue":"6","key":"10852_CR8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3390\/ijms20061442","volume":"20","author":"M Krzystanek","year":"2019","unstructured":"Krzystanek M, Pa\u0142asz A (2019) NMDA receptor model of antipsychotic drug-induced hypofrontality. Int J Mol Sci 20(6):1442","journal-title":"Int J Mol Sci"},{"key":"10852_CR9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-822290-4.00015-3","volume":"183","author":"AD Bono","year":"2021","unstructured":"Bono AD et al (2021) Mood and emotional disorders associated with parkinsonism, huntington disease, and other movement disorders. Handb Clin Neurol 183:175\u2013196","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10852_CR10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajhg.2021.12.002","volume":"109","author":"DR Langbehn","year":"2022","unstructured":"Langbehn DR (2022) Longer CAG repeat length is associated with shorter survival after disease onset in huntington disease. Am J Hum Genet 109(1):172\u2013179","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10852_CR11","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.3390\/ijms21124282","volume":"21","author":"B Lontay","year":"2020","unstructured":"Lontay B et al (2020) How do post-translational modifications influence the pathomechanistic landscape of huntington\u2019s disease? A comprehensive review. Int J Mol Sci 21(12):4282","journal-title":"Int J Mol Sci"},{"key":"10852_CR12","doi-asserted-by":"crossref","first-page":"100056","DOI":"10.1016\/j.prdoa.2020.100056","volume":"3","author":"EM Gatto","year":"2020","unstructured":"Gatto EM et al (2020) Huntington disease: advances in the Understanding of its mechanisms. Clin Parkinsonism Relat Disorders 3:100056","journal-title":"Clin Parkinsonism Relat Disorders"},{"key":"10852_CR13","doi-asserted-by":"crossref","unstructured":"Prajapati C et al Natural sources of drugs for neurodegenerative diseases, in Neurodegenerative diseases. CRC. pp. 120\u2013134","DOI":"10.1201\/9781032620442-10"},{"issue":"16","key":"10852_CR14","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","volume":"22","author":"A Kim","year":"2021","unstructured":"Kim A et al (2021) New avenues for the treatment of huntington\u2019s disease. Int J Mol Sci 22(16):8363","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10852_CR15","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1007\/s12325-020-01519-3","volume":"37","author":"R Devi","year":"2020","unstructured":"Devi R et al (2020) A narrative review of the patient journey through the lens of non-communicable diseases in low-and middle-income countries. Adv Therapy 37(12):4808\u20134830","journal-title":"Adv Therapy"},{"key":"10852_CR16","doi-asserted-by":"crossref","unstructured":"Jose L et al (2023) Non-invasive neuromodulation methods to alleviate symptoms of huntington\u2019s disease: a systematic review of the literature. Journal of Clinical Medicine, 12(5): p. 2002","DOI":"10.3390\/jcm12052002"},{"issue":"23","key":"10852_CR17","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.3390\/diagnostics13233592","volume":"13","author":"S Ganesh","year":"2023","unstructured":"Ganesh S et al (2023) Exploring huntington\u2019s disease diagnosis via artificial intelligence models: A comprehensive review. Diagnostics 13(23):3592","journal-title":"Diagnostics"},{"issue":"7","key":"10852_CR18","first-page":"12","volume":"31","author":"S Fisher","year":"2020","unstructured":"Fisher S et al (2020) International population-based health surveys linked to outcome data: a new resource for public health and epidemiology. Health Rep 31(7):12","journal-title":"Health Rep"},{"key":"10852_CR19","doi-asserted-by":"crossref","first-page":"1033299","DOI":"10.3389\/fped.2022.1033299","volume":"10","author":"SV Raga","year":"2022","unstructured":"Raga SV et al (2022) A case for genomic medicine in South African paediatric patients with neuromuscular disease. Front Pead 10:1033299","journal-title":"Front Pead"},{"key":"10852_CR20","unstructured":"Duarte F (2023) Development of Gene Editing-based Therapeutic Strategies for Huntington\u2019s Disease. \u00e9diteur non identifi&#233"},{"issue":"12","key":"10852_CR21","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A et al (2022) Prevalence and incidence of huntington\u2019s disease: an updated systematic review and meta-analysis. Mov Disord 37(12):2327\u20132335","journal-title":"Mov Disord"},{"issue":"9","key":"10852_CR22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T et al (2012) The incidence and prevalence of huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord 27(9):1083\u20131091","journal-title":"Mov Disord"},{"key":"10852_CR23","unstructured":"Carreon RP (2022) Resignation, in the absence of cure: A narrative study on the illness experience of huntington\u2019s disease. Liverpool John Moores University (United Kingdom)"},{"key":"10852_CR24","unstructured":"Begum AU, Fathima J (2020) HUNTINGTON\u2019S DISEASE: A RARE NEURODEGERATIVE DISORDER."},{"key":"10852_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-020-02494-7","volume":"14","author":"S Lesinskien\u0117","year":"2020","unstructured":"Lesinskien\u0117 S et al (2020) Juvenile huntington\u2019s disease: two case reports and a review of the literature. J Med Case Rep 14:1\u20135","journal-title":"J Med Case Rep"},{"key":"10852_CR26","doi-asserted-by":"crossref","first-page":"946822","DOI":"10.3389\/fnins.2022.946822","volume":"16","author":"KM Donnelly","year":"2022","unstructured":"Donnelly KM et al (2022) Hunting for the cause: evidence for prion-like mechanisms in huntington\u2019s disease. Front NeuroSci 16:946822","journal-title":"Front NeuroSci"},{"issue":"4","key":"10852_CR27","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","volume":"176","author":"AS Dickey","year":"2018","unstructured":"Dickey AS, La Spada AR (2018) Therapy development in huntington disease: from current strategies to emerging opportunities. Am J Med Genet Part A 176(4):842\u2013861","journal-title":"Am J Med Genet Part A"},{"issue":"3","key":"10852_CR28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/mdc3.13375","volume":"9","author":"AE Rosser","year":"2022","unstructured":"Rosser AE, Jones L (2022) Huntington\u2019s disease gene hunters: an expanding Tale. Mov Disorders Clin Pract 9(3):330","journal-title":"Mov Disorders Clin Pract"},{"issue":"4","key":"10852_CR29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1389200223666220321103942","volume":"23","author":"E Srinivasan","year":"2022","unstructured":"Srinivasan E, Ram V, Rajasekaran R (2022) A review on huntington protein: insight into protein aggregation and therapeutic interventions. Curr Drug Metab 23(4):260\u2013282","journal-title":"Curr Drug Metab"},{"key":"10852_CR30","doi-asserted-by":"crossref","unstructured":"Vasilopoulou MA, Papaevgeniou N, Chondrogianni N (2021) Proteasome fate in aging and proteinopathies, in Proteostasis and proteolysis. CRC, pp 151\u2013166","DOI":"10.1201\/9781003048138-12"},{"key":"10852_CR31","unstructured":"Wu W-l et al (2025) Molecular mechanisms of excitotoxicity and their relevance to the pathogenesis of neurodegenerative diseases\u2014an update. Acta Pharmacol Sin,: p. 1\u201314"},{"key":"10852_CR32","doi-asserted-by":"crossref","unstructured":"Goel F, Dobhal V, Singh S (2025) Protective effects of diacerein against quinolinic acid\u2013induced huntington\u2019s disease\u2013like symptoms in adult zebrafish by targeting GSK-3\u03b2 signalling. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, pp 1\u201323","DOI":"10.1007\/s00210-025-03976-5"},{"issue":"12","key":"10852_CR33","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3390\/antiox11122377","volume":"11","author":"L Wang","year":"2022","unstructured":"Wang L et al (2022) Nrf2 regulates oxidative stress and its role in cerebral ischemic stroke. Antioxidants 11(12):2377","journal-title":"Antioxidants"},{"issue":"10","key":"10852_CR34","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/molecules27103194","volume":"27","author":"A Rauf","year":"2022","unstructured":"Rauf A et al (2022) Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases. Molecules 27(10):3194","journal-title":"Molecules"},{"key":"10852_CR35","doi-asserted-by":"crossref","unstructured":"Berth SH, Lloyd TE (2023) Disruption of axonal transport in neurodegeneration. J Clin Investig, 133(11)","DOI":"10.1172\/JCI168554"},{"issue":"1","key":"10852_CR36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41380-021-01092-3","volume":"27","author":"Z Yan","year":"2022","unstructured":"Yan Z, Rein B (2022) Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications. Mol Psychiatry 27(1):445\u2013465","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10852_CR37","doi-asserted-by":"crossref","first-page":"e13012","DOI":"10.1111\/bpa.13012","volume":"32","author":"Z Chen","year":"2022","unstructured":"Chen Z, Rasheed M, Deng Y (2022) The epigenetic mechanisms involved in mitochondrial dysfunction: implication for parkinson\u2019s disease. Brain Pathol 32(3):e13012","journal-title":"Brain Pathol"},{"issue":"4","key":"10852_CR38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.14336\/AD.2021.1212","volume":"13","author":"N Qin","year":"2022","unstructured":"Qin N, Geng A, Xue R (2022) Activated or impaired: an overview of DNA repair in neurodegenerative diseases. Aging Disease 13(4):987","journal-title":"Aging Disease"},{"key":"10852_CR39","doi-asserted-by":"crossref","unstructured":"Chauhan K, Goel F, Singh S (2024) Apigenin protects melanocytes and improve tyrosinase activity in a hydroquinone induced vitiligo mouse model targeting P38 MAP kinase signaling: histopathology and immunohistochemistry analysis, vol 397. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, pp 4859\u20134869. 7","DOI":"10.1007\/s00210-023-02917-4"},{"key":"10852_CR40","unstructured":"Woodard CL (2020) Automated behavioural testing and drug treatment in mouse models of Huntington\u2019s disease. University of British Columbia"},{"key":"10852_CR41","doi-asserted-by":"crossref","unstructured":"Bhushan R, Goel F, Singh S (2025) Beyond dopamine: novel therapeutic pathways for Parkinson\u2019s disease through receptor signaling. CNS & Neurological Disorders-Drug Targets","DOI":"10.2174\/0118715273325667241212041540"},{"issue":"13","key":"10852_CR42","doi-asserted-by":"crossref","first-page":"10809","DOI":"10.3390\/ijms241310809","volume":"24","author":"AV Ciurea","year":"2023","unstructured":"Ciurea AV et al (2023) Unraveling molecular and genetic insights into neurodegenerative diseases: advances in Understanding alzheimer\u2019s, parkinson\u2019s, and huntington\u2019s diseases and amyotrophic lateral sclerosis. Int J Mol Sci 24(13):10809","journal-title":"Int J Mol Sci"},{"key":"10852_CR43","doi-asserted-by":"crossref","unstructured":"Thompson LM, Orr HT (2023) HD and SCA1: Tales from two 30-year journeys since gene discovery. Neuron","DOI":"10.1016\/j.neuron.2023.09.036"},{"key":"10852_CR44","doi-asserted-by":"crossref","unstructured":"Prajapati C et al (2025) Intellectual property rights in neuroprotective biomaterials, in Biomaterials and neurodegenerative disorders. Springer, pp 251\u2013269","DOI":"10.1007\/978-981-97-9959-6_10"},{"key":"10852_CR45","doi-asserted-by":"crossref","first-page":"517415","DOI":"10.3389\/fimmu.2020.00337","volume":"11","author":"O Fatoba","year":"2020","unstructured":"Fatoba O et al (2020) Immunotherapies in huntington\u2019s disease and \u03b1-Synucleinopathies. Front Immunol 11:517415","journal-title":"Front Immunol"},{"issue":"31","key":"10852_CR46","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.2174\/0929867326666190621101909","volume":"27","author":"E Tellone","year":"2020","unstructured":"Tellone E, Galtieri A, Ficarra S (2020) Reviewing biochemical implications of normal and mutated Huntingtin in huntington\u2019s disease. Curr Med Chem 27(31):5137\u20135158","journal-title":"Curr Med Chem"},{"key":"10852_CR47","doi-asserted-by":"crossref","unstructured":"Ramakrishna K et al (2023) WNT-\u03b2 Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective. Diseases 11, 89. 2023","DOI":"10.3390\/diseases11030089"},{"key":"10852_CR48","unstructured":"Islam MR et al (2023) A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington\u2019s disease. Mol Neurobiol,: p. 1\u201334"},{"issue":"1","key":"10852_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21608\/rpbs.2018.4037.1005","volume":"2","author":"M Megahed","year":"2018","unstructured":"Megahed M et al (2018) Huntington\u2019s disease and NMDA receptors; a new arena for therapeutic development. Records Pharm Biomedical Sci 2(1):1\u201313","journal-title":"Records Pharm Biomedical Sci"},{"issue":"1","key":"10852_CR50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1073858420972662","volume":"28","author":"C Cepeda","year":"2022","unstructured":"Cepeda C, Levine MS (2022) Synaptic dysfunction in huntington\u2019s disease: lessons from genetic animal models. Neuroscientist 28(1):20\u201340","journal-title":"Neuroscientist"},{"key":"10852_CR51","unstructured":"Fatoba O (2018) The neuroprotective role of neuropeptide-Y in the R6\/2 mouse and PC12 cell models of Huntington\u2019s disease via Y2 receptor activation. Dissertation, Bochum, Ruhr-Universit\u00e4t Bochum, 2017"},{"key":"10852_CR52","doi-asserted-by":"crossref","first-page":"1193130","DOI":"10.3389\/fcell.2023.1193130","volume":"11","author":"MJ Pereira","year":"2023","unstructured":"Pereira MJ et al (2023) Chemogenetic manipulation of astrocyte activity at the synapse\u2014a gateway to manage brain disease. Front Cell Dev Biology 11:1193130","journal-title":"Front Cell Dev Biology"},{"issue":"2","key":"10852_CR53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/ijms23020780","volume":"23","author":"S Maity","year":"2022","unstructured":"Maity S et al (2022) Impact of ER stress and ER-mitochondrial crosstalk in huntington\u2019s disease. Int J Mol Sci 23(2):780","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10852_CR54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JHD-160221","volume":"5","author":"C Rangel-Barajas","year":"2016","unstructured":"Rangel-Barajas C, Rebec GV (2016) Dysregulation of corticostriatal connectivity in huntington\u2019s disease: a role for dopamine modulation. J Huntington\u2019s Disease 5(4):303\u2013331","journal-title":"J Huntington\u2019s Disease"},{"issue":"6","key":"10852_CR55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/23.6.168247","volume":"23","author":"L Roizin","year":"1975","unstructured":"Roizin L et al (1975) Acid-beta-glycerophosphatase reaction products in the central nervous system mitochondria following x-ray irradiation. J Histochem Cytochemistry 23(6):402\u2013410","journal-title":"J Histochem Cytochemistry"},{"issue":"1386","key":"10852_CR56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1098\/rstb.1999.0451","volume":"354","author":"N Aronin","year":"1999","unstructured":"Aronin N et al (1999) Are there multiple pathways in the pathogenesis of huntington\u2019sdisease?? Philosophical Trans Royal Soc Lond Ser B: Biol Sci 354(1386):995\u20131003","journal-title":"Philosophical Trans Royal Soc Lond Ser B: Biol Sci"},{"issue":"2","key":"10852_CR57","first-page":"1","volume":"75","author":"A Pal","year":"2025","unstructured":"Pal A, Goel F, Garg VK (2025) From genetics to function: the role of ABCA12 in autism neurobiology. J Mol Neurosci 75(2):1\u201313","journal-title":"J Mol Neurosci"},{"issue":"1","key":"10852_CR58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12974-022-02419-9","volume":"19","author":"K-P Chen","year":"2022","unstructured":"Chen K-P et al (2022) A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a Transgenic mouse model of huntington\u2019s disease. J Neuroinflamm 19(1):56","journal-title":"J Neuroinflamm"},{"key":"10852_CR59","doi-asserted-by":"crossref","first-page":"769184","DOI":"10.3389\/fmolb.2021.769184","volume":"8","author":"OD Jarosi\u0144ska","year":"2021","unstructured":"Jarosi\u0144ska OD, R\u00fcdiger SG (2021) Molecular strategies to target protein aggregation in huntington\u2019s disease. Front Mol Biosci 8:769184","journal-title":"Front Mol Biosci"},{"issue":"16","key":"10852_CR60","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1016\/j.jmb.2020.06.021","volume":"432","author":"JC Boatz","year":"2020","unstructured":"Boatz JC et al (2020) Protofilament structure and supramolecular polymorphism of aggregated mutant Huntingtin exon 1. J Mol Biol 432(16):4722\u20134744","journal-title":"J Mol Biol"},{"issue":"11","key":"10852_CR61","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43587-023-00502-1","volume":"3","author":"E Llamas","year":"2023","unstructured":"Llamas E et al (2023) In planta expression of human polyQ-expanded Huntingtin fragment reveals mechanisms to prevent disease-related protein aggregation. Nat Aging 3(11):1345\u20131357","journal-title":"Nat Aging"},{"key":"10852_CR62","doi-asserted-by":"crossref","first-page":"120009","DOI":"10.1016\/j.lfs.2021.120009","volume":"285","author":"BR Pinho","year":"2021","unstructured":"Pinho BR et al (2021) Allosteric activation of Hsp70 reduces mutant Huntingtin levels, the clustering of N-terminal fragments, and their nuclear accumulation. Life Sci 285:120009","journal-title":"Life Sci"},{"issue":"14","key":"10852_CR63","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2174\/1389450122666210224105945","volume":"22","author":"A Sharma","year":"2021","unstructured":"Sharma A et al (2021) Mitochondrial dysfunction in huntington\u2019s disease: pathogenesis and therapeutic opportunities. Curr Drug Targets 22(14):1637\u20131667","journal-title":"Curr Drug Targets"},{"key":"10852_CR64","doi-asserted-by":"crossref","first-page":"101358","DOI":"10.1016\/j.arr.2021.101358","volume":"69","author":"C-L Chuang","year":"2021","unstructured":"Chuang C-L, Demontis F (2021) Systemic manifestation and contribution of peripheral tissues to huntington\u2019s disease pathogenesis. Ageing Res Rev 69:101358","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10852_CR65","doi-asserted-by":"crossref","first-page":"NS20200010","DOI":"10.1042\/NS20200010","volume":"4","author":"RS Lahue","year":"2020","unstructured":"Lahue RS (2020) New developments in huntington\u2019s disease and other triplet repeat diseases: DNA repair turns to the dark side. Neuronal Signal 4(4):NS20200010","journal-title":"Neuronal Signal"},{"issue":"1","key":"10852_CR66","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/s41598-021-83000-x","volume":"11","author":"Z-YA Ou","year":"2021","unstructured":"Ou Z-YA et al (2021) Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for huntington\u2019s disease. Sci Rep 11(1):3481","journal-title":"Sci Rep"},{"key":"10852_CR67","unstructured":"Ly S (2020) Investigating the role of mutant Huntingtin mRNA in huntington\u2019s disease. University of Massachusetts Medical School"},{"key":"10852_CR68","unstructured":"Passoni A (2023) Innovative therapeutic strategy targeting neurons with cholesterol in huntington\u2019s disease: from preclinical studies to clinical trial readiness. The Open University"},{"issue":"2","key":"10852_CR69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen SJ et al (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 138(2):155\u2013175","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10852_CR70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12272-024-01499-w","volume":"47","author":"A Shafie","year":"2024","unstructured":"Shafie A et al (2024) Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of huntington\u2019s disease. Arch Pharm Res 47(6):571\u2013595","journal-title":"Arch Pharm Res"},{"key":"10852_CR71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gde.2020.10.006","volume":"67","author":"RE Brown","year":"2021","unstructured":"Brown RE, Freudenreich CH (2021) Structure-forming repeats and their impact on genome stability. Curr Opin Genet Dev 67:41\u201351","journal-title":"Curr Opin Genet Dev"},{"issue":"1","key":"10852_CR72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JHD-200423","volume":"10","author":"X Zhao","year":"2021","unstructured":"Zhao X et al (2021) Modifiers of somatic repeat instability in mouse models of Friedreich ataxia and the fragile X-related disorders: implications for the mechanism of somatic expansion in huntington\u2019s disease. J Huntington\u2019s Disease 10(1):149\u2013163","journal-title":"J Huntington\u2019s Disease"},{"issue":"3","key":"10852_CR73","first-page":"29","volume":"15","author":"A Nikkhah","year":"2021","unstructured":"Nikkhah A (2021) A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders. Iran J Child Neurol 15(3):29","journal-title":"Iran J Child Neurol"},{"issue":"8","key":"10852_CR74","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2021.1876666","volume":"22","author":"JS Gibson","year":"2021","unstructured":"Gibson JS, Claassen DO (2021) State-of-the-art Pharmacological approaches to reduce chorea in huntington\u2019s disease. Expert Opin Pharmacother 22(8):1015\u20131024","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10852_CR75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ et al (2022) Potential disease-modifying therapies for huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol 21(7):645\u2013658","journal-title":"Lancet Neurol"},{"key":"10852_CR76","doi-asserted-by":"crossref","unstructured":"Alwindi M, Bizanti A (2023) Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions. Heliyon","DOI":"10.1016\/j.heliyon.2023.e22413"},{"key":"10852_CR77","doi-asserted-by":"crossref","unstructured":"Claassen D et al (2023) Real-World Effectiveness and Safety of Deutetrabenazine in Combination with Antipsychotic Drugs in Patients With Chorea Associated With Huntington Disease (P2-11.010). AAN Enterprises","DOI":"10.1212\/WNL.0000000000201971"},{"key":"10852_CR78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2022.11.004","volume":"105","author":"RL Andriessen","year":"2022","unstructured":"Andriessen RL et al (2022) Psychotropic medication use in huntington\u2019s disease: A retrospective cohort study. Parkinsonism Relat Disord 105:69\u201374","journal-title":"Parkinsonism Relat Disord"},{"key":"10852_CR79","unstructured":"Badadhe S et al (2024) Huntington disease: brief overview. Innovative J Med Healthc Res,: p. 1\u201311"},{"issue":"1","key":"10852_CR80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s42466-023-00285-1","volume":"5","author":"C Saft","year":"2023","unstructured":"Saft C et al (2023) Symptomatic treatment options for huntington\u2019s disease (guidelines of the German neurological Society). Neurol Res Pract 5(1):61","journal-title":"Neurol Res Pract"},{"key":"10852_CR81","doi-asserted-by":"crossref","unstructured":"Gray M et al (2024) Genetic mouse models to explore Huntington\u2019s disease mechanisms and therapeutic strategies, in Huntington\u2019s Disease. Elsevier, pp 427\u2013454","DOI":"10.1016\/B978-0-323-95672-7.00013-3"},{"issue":"12","key":"10852_CR82","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/biomedicines11123331","volume":"11","author":"G Nittari","year":"2023","unstructured":"Nittari G et al (2023) Rodent models of huntington\u2019s disease: an overview. Biomedicines 11(12):3331","journal-title":"Biomedicines"},{"key":"10852_CR83","doi-asserted-by":"crossref","first-page":"617229","DOI":"10.3389\/fnmol.2020.617229","volume":"13","author":"E Etxeberria-Rekalde","year":"2021","unstructured":"Etxeberria-Rekalde E et al (2021) Quantification of huntington\u2019s disease related markers in the R6\/2 mouse model. Front Mol Neurosci 13:617229","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"10852_CR84","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/17460441.2023.2201493","volume":"18","author":"S Upadhayay","year":"2023","unstructured":"Upadhayay S, Jamwal S, Kumar P (2023) Animal models of huntington\u2019s disease and their applicability to novel drug discovery and development. Expert Opin Drug Discov 18(5):527\u2013538","journal-title":"Expert Opin Drug Discov"},{"key":"10852_CR85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.12703\/r\/10-77","volume":"10","author":"J Kaye","year":"2021","unstructured":"Kaye J, Reisine T, Finkbeiner S (2021) Huntington\u2019s disease mouse models: unraveling the pathology caused by CAG repeat expansion. Fac Reviews 10:77","journal-title":"Fac Reviews"},{"key":"10852_CR86","doi-asserted-by":"crossref","unstructured":"Sawant N et al (2021) Mitochondrial abnormalities and synaptic damage in huntington\u2019s disease: a focus on defective mitophagy and mitochondria-targeted therapeutics. Mol Neurobiol,: p. 1\u201328","DOI":"10.1007\/s12035-021-02556-x"},{"issue":"2","key":"10852_CR87","doi-asserted-by":"crossref","first-page":"275","DOI":"10.24272\/j.issn.2095-8137.2023.199","volume":"45","author":"B Han","year":"2024","unstructured":"Han B et al (2024) Large animal models for huntington\u2019s disease research. Zoological Res 45(2):275","journal-title":"Zoological Res"},{"key":"10852_CR88","doi-asserted-by":"crossref","unstructured":"Lelos MJ (2022) Investigating cell therapies in animal models of Parkinson\u2019s and Huntington\u2019s disease: Current challenges and considerations, in International Review of Neurobiology. Elsevier. pp. 159\u2013189","DOI":"10.1016\/bs.irn.2022.09.005"},{"issue":"9","key":"10852_CR89","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/biology11091251","volume":"11","author":"A Banstola","year":"2022","unstructured":"Banstola A, Reynolds JN (2022) The sheep as a large animal model for the investigation and treatment of human disorders. Biology 11(9):1251","journal-title":"Biology"},{"issue":"8","key":"10852_CR90","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/ph17081048","volume":"17","author":"H Guo","year":"2024","unstructured":"Guo H et al (2024) The pivotal role of preclinical animal models in Anti-Cancer drug discovery and personalized Cancer therapy strategies. Pharmaceuticals 17(8):1048","journal-title":"Pharmaceuticals"},{"key":"10852_CR91","doi-asserted-by":"crossref","first-page":"105642","DOI":"10.1016\/j.bioorg.2022.105642","volume":"120","author":"SJ Devadiga","year":"2022","unstructured":"Devadiga SJ, Bharate SS (2022) Recent developments in the management of huntington\u2019s disease. Bioorg Chem 120:105642","journal-title":"Bioorg Chem"},{"issue":"8","key":"10852_CR92","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.3390\/ijms23084153","volume":"23","author":"AM Hersh","year":"2022","unstructured":"Hersh AM, Alomari S, Tyler BM (2022) Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci 23(8):4153","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10852_CR93","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/ijms22094820","volume":"22","author":"V La Cognata","year":"2021","unstructured":"La Cognata V, Morello G, Cavallaro S (2021) Omics data and their integrative analysis to support stratified medicine in neurodegenerative diseases. Int J Mol Sci 22(9):4820","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10852_CR94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/cells13090745","volume":"13","author":"DB Pazzin","year":"2024","unstructured":"Pazzin DB et al (2024) Induced pluripotent stem cells and organoids in advancing neuropathology research and therapies. Cells 13(9):745","journal-title":"Cells"},{"key":"10852_CR95","doi-asserted-by":"crossref","unstructured":"Christodoulou CC, Aristeidou D, Zamba-Papanicolaou E (2025) A comprehensive review of Pharmacological and Non-Pharmacological therapies for huntington\u2019s disease. Med Res Archives, 13(2)","DOI":"10.18103\/mra.v13i2.6279"},{"issue":"1","key":"10852_CR96","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/antiox11010165","volume":"11","author":"LR Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez LR et al (2022) Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases? Antioxidants 11(1):165","journal-title":"Antioxidants"},{"issue":"3","key":"10852_CR97","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/biom12030363","volume":"12","author":"F Bog\u00e1r","year":"2022","unstructured":"Bog\u00e1r F, F\u00fcl\u00f6p L, Penke B (2022) Novel therapeutic target for prevention of neurodegenerative diseases: modulation of neuroinflammation with Sig-1R ligands. Biomolecules 12(3):363","journal-title":"Biomolecules"},{"key":"10852_CR98","doi-asserted-by":"crossref","first-page":"105857","DOI":"10.1016\/j.nbd.2022.105857","volume":"173","author":"S Lenoir","year":"2022","unstructured":"Lenoir S et al (2022) Pridopidine rescues bdnf\/trkb trafficking dynamics and synapse homeostasis in a huntington disease brain-on-a-chip model. Neurobiol Dis 173:105857","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10852_CR99","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14728222.2020.1805435","volume":"24","author":"JM Brimson","year":"2020","unstructured":"Brimson JM et al (2020) Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets 24(10):1009\u20131028","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"10852_CR100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41582-020-0377-8","volume":"16","author":"MA Myszczynska","year":"2020","unstructured":"Myszczynska MA et al (2020) Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nat Reviews Neurol 16(8):440\u2013456","journal-title":"Nat Reviews Neurol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10852-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T04:26:59Z","timestamp":1766896019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10852-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10852"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10852-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate(Applicable if animals\/human or cell lines are used)"}},{"value":"The authors affirm that they have no known financial or interpersonal conflicts that would have seemed to have an impact on the research presented in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"754"}}